ORTEXORTEX News
Tracking SNPS? Get live short interest, options flow, and signals on ORTEX.Sign up free →
SN
ConfluenceSNPS

BNP Paribas Lifts SNPS from Underperform as Options Turn Bullish

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 24 Sept 2026, 18:47

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit
ORTEX chart of Synopsys, Inc. (SNPS) share price and short interest (% of free float), three months to September 23, 2026
ORTEX data as of 24 Sept 2026, 18:47

Three distinct signals converged on SNPS Wednesday. An analyst upgrade, a sharp shift in options positioning, and a cost-to-borrow move arrived within 24 hours — each pointing in broadly the same direction.

The Upgrade That Stands Out

BNP Paribas analyst Andrew DeGasperi upgraded Synopsys to Neutral from Underperform today, setting a $420 price target against a current price of $413. The move matters less for where BNP landed — Neutral is hardly a ringing endorsement — and more for what it signals: one of the last notable bears on the stock is stepping back.

The broader analyst community is considerably more constructive. Seventeen of 19 covering analysts rate the stock a Buy. The consensus mean target sits at $546, implying 32% upside from current levels. Wells Fargo raised its rating to Overweight on September 10. Morgan Stanley upgraded to Overweight on September 8. The direction of analyst travel has been clearly upward.

Earnings are due September 30. The most recent report, in late August, sent the stock up 13.7% in a single session.

Options Traders Rotate Into Calls

The put-call ratio tells a consistent story. It sat at 0.92 on September 23, some 2.3 standard deviations below its 20-day mean of 1.13. The ratio has been dropping steadily. As recently as early September it was trading above 1.20 — a level associated with hedging demand. Now calls are comfortably outpacing puts.

The 52-week low on the PCR is 0.43, so there is room to run on the bullish side. But the velocity of the move is notable. The shift from above 1.20 to below 0.93 has happened in roughly three weeks, aligned with the sequence of analyst upgrades.

Cost to Borrow: Worth Watching, Not Alarming

Cost to borrow rose 76% in one week to 0.48%. The direction is worth flagging. But the absolute level remains low — well under 1% — and availability is extremely loose at 6,882% (over 188 million shares available to borrow versus roughly 5.5 million currently shorted). The borrow market is not under any meaningful stress.

Short interest stands at 2.9% of free float and has drifted only modestly higher over the past month. This is not a heavily shorted stock, and the CTB move reflects a small nominal increase in borrow demand rather than a genuine squeeze dynamic.

Data Summary

  • Price: $413.06, up 9.1% over one week
  • Analyst consensus: Buy; 17 Buy, 2 Hold; mean target $546
  • BNP Paribas upgrade: Underperform → Neutral, $420 target (Sept 24)
  • Put-call ratio: 0.92, –2.3 SD below 20-day mean of 1.13
  • Short interest: 2.9% of free float; 5.48M shares short (Sept 23)
  • Cost to borrow: 0.48%, up 76% week-on-week; availability at 6,882%
  • Next earnings: September 30

Watch: Whether SNPS can close the gap toward the $546 consensus target heading into earnings — and whether the PCR compression holds or reverses on any pre-print volatility.

Against its peers

Shares moved +9.1% over the past week against a median of +9.9% for its closest peers.

Stocks in this article

See the live data behind this article on ORTEX.

Open SNPS on ORTEX →

How this article was generated

Generated
24 Sept 2026, 18:49
Data as of
24 Sept 2026, 18:47
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.